Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PDE5 inhibitors: are there differences?

Culley C Carson1

  • 1Division of Urology, University of North Carolina, Chapel Hill, North Carolina 27759-7235, USA.

The Canadian Journal of Urology
|March 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Society of Urologic Prosthetic Surgeons' Coding and Billing Position Statement on Ancillary/Adjunct Penile Prosthesis Surgical Procedures: Part I.

Urology·2024
Same author

Reduced Resident Work Hours in Urology: The History and Impact of Duty Hour Restrictions.

Urology practice·2023
Same author

Editorial Commentary.

Urology practice·2023
Same author

Why men's health?

Postgraduate medicine·2020
Same author

Artificial urinary sphincter: current status and future directions.

Asian journal of andrology·2020
Same author

Infection Retardant Coatings Impact on Bacterial Presence in Penile Prosthesis Surgery: A Multicenter Study.

Urology·2018
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

Oral phosphodiesterase type 5 (PDE5) inhibitors like sildenafil, tadalafil, and vardenafil effectively treat erectile dysfunction (ED). While sharing a mechanism, they have distinct pharmacokinetic profiles, with limited clinical data to guide selection for specific patients.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Oral phosphodiesterase type 5 (PDE5) inhibitors have revolutionized erectile dysfunction (ED) treatment.
  • Sildenafil, tadalafil, and vardenafil are effective, safe, and reliable oral agents for ED of all severities and etiologies.

Purpose of the Study:

  • To summarize current data on PDE5 inhibitors regarding efficacy, safety, and use in other conditions.
  • To highlight the similarities and differences among sildenafil, tadalafil, and vardenafil.
  • To address the challenges in differentiating between PDE5 inhibitors for clinical selection.

Main Methods:

  • Review of current data on PDE5 inhibitors.
  • Comparison of pharmacokinetic and pharmacodynamic profiles.
  • Discussion of clinical efficacy and safety data.

Related Experiment Videos

Main Results:

  • All three PDE5 inhibitors are effective for ED across various patient groups.
  • Sildenafil has the longest patient experience and robust safety data.
  • Tadalafil offers a longer half-life, and vardenafil shows high potency and efficacy in some cases.
  • Emerging data suggest PDE5 inhibitors may aid in treating lower urinary tract symptoms.

Conclusions:

  • PDE5 inhibitors are effective ED treatments with distinct profiles.
  • Limited head-to-head trials make clinical differentiation challenging for healthcare providers.
  • Further research is needed to guide optimal selection and switching strategies for PDE5 inhibitors.